Treprostinil

Two European studies highlight the need for better diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease (ILD). The first study, published in *Pulmonary Circulation*, found that early recognition of symptoms could be life-changing, with shortness of breath being the most distressing symptom. The second study, published in *ERJ Open Research*, revealed significant unmet needs in managing this rare disease, emphasizing the need for comprehensive screening, diagnostic protocols, and effective treatments.

A New Jersey federal court awarded Sandoz over $70 million in its lawsuit against United Therapeutics for blocking the sale of a generic hypertension drug, finding that Sandoz lost more than $137 million in profits as a result of United Therapeutics breaching a 2015 settlement agreement.

United Therapeutics reports Q3 2024 revenue of $748.9M, up 23% YoY. CEO Martine Rothblatt highlights a $3B annual revenue run rate and upcoming clinical data reads. President Michael Benkowitz notes increasing demand for products serving pulmonary hypertension and high-risk neuroblastoma patients. Key financial highlights include net income of $309.1M and diluted EPS of $6.39.

SCOTUS denied UTC's cert petition, allowing Liquidia to launch Yutrpia® after UTC's FDA exclusivity expires on May 23, 2025. The decision ends patent litigation, invalidating UTC's ’793 patent, but Liquidia must wait for final FDA approval.

U.S. Supreme Court denied United Therapeutics' appeal, affirming all claims of Patent No. 10,716,793 are invalid. Liquidia's decisions on non-infringement of three patents are final. FDA granted tentative approval for YUTREPIA inhalation powder for PAH and PH-ILD, with final approval pending after Tyvaso DPI exclusivity expires in 2025.

United Therapeutics announces presentations on Tyvaso DPI® at CHEST 2024, including long-term outcomes from the BREEZE study, and sponsors symposium on clinical pearls and drug-device characteristics.

American Century Companies Inc. increased its stake in United Therapeutics by 42.8% in Q2, owning 41,233 shares worth $13.135 million. Other investors also increased their holdings, with institutional investors owning 94.08% of the company's stock. CEO Martine A. Rothblatt sold 3,600 shares at $315.97 each, reducing her ownership to 130 shares valued at $41,076.10. CFO James Edgemond sold 7,802 shares at $345.41 each, leaving him with 3,210 shares worth $1.1 million. United Therapeutics reported $5.85 earnings per share for Q2, missing estimates by $0.48, with revenue up 19.8% YoY. Analysts predict $24.86 earnings per share for the current fiscal year. StockNews.com downgraded United Therapeutics from a "strong-buy" to a "buy" rating, while Morgan Stanley increased their price objective from $310.00 to $321.00.